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Hypertrophic cardiomyopathy (HCM), the most common 
genetically transmitted cardiac disorder, has been the fo-
cus of extensive research over the past 50 years. HCM is 
a multifaceted disease with highly heterogeneous genetic 
background, phenotypic expression, clinical presentation, 
and long-term outcome. Though most patients have an 
indolent course with a life expectancy comparable to that 
of the general population, early diagnosis and accurate 
risk profiling are essential to identify the sizeable subset 
at increased risk of sudden cardiac death or disease pro-
gression and heart failure–related complications, requir-
ing aggressive management options. Imaging has a central 
role in the diagnosis and prognostic assessment of HCM 
patients, as well as screening of potentially affected family 
members. In this context, magnetic resonance (MR) imag-
ing has recently emerged as an ideal complement to trans-
thoracic echocardiography. Its multiparametric approach, 
fusing spatial, contrast, and temporal resolution, provides 
the clinician with detailed characterization of the HCM 
phenotype and assessment of its functional consequences 
including causes and site of dynamic obstruction, pres-
ence and extent of myocardial perfusion abnormalities, 
and fibrosis. Moreover, MR is key in differentiating HCM 
from “phenocopies”—that is, hearts with similar morphol-
ogy but profoundly different etiology, such as amyloid or 
Anderson-Fabry disease. Long term, the incremental in-
formation provided by MR is relevant to planning of sep-
tal reduction therapies, identification of the early stages 
of end-stage progression, and stratification of arrhythmic 
risk. The aim of this review is to depict the increasingly 
important role of MR imaging in relation to the complexity 
of HCM, highlighting its role in clinical decision making.
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Essentials
 n Any attempt toward a simple def-
inition of hypertrophic cardiomy-
opathy (HCM) has been ham-
pered by the fact that, rather 
than a single well-defined entity, 
the disease includes a spectrum 
of conditions; clinical presenta-
tion ranges from asymptomatic 
individuals with mild pheno-
types—or even phenotype-nega-
tive mutation carriers—to se-
verely symptomatic patients with 
dynamic left ventricular outflow 
obstruction or hypokinetic-
restrictive end-stage disease.
 n Disease-causing sarcomere gene 
mutations do not account for the 
great variability of HCM pheno-
types and clinical profiles—
observed even within the same 
families—pointing to additional 
and poorly understood genetic, 
epigenetic, and environmental 
factors as critical modifiers of its 
ultimate expression; adding to 
this complexity, mutations in the 
same cardiac sarcomere protein 
genes may result in dilated, re-
strictive, and noncompaction 
phenotypes rather than HCM.
 n Since its introduction in the mid-
1980s, cardiac MR imaging has 
evolved into a multiparametric 
imaging modality allowing a truly 
comprehensive patient- and dis-
ease-tailored appraisal of HCM, 
providing information on major 
areas of interest including car-
diac phenotype, its functional 
and hemodynamic characteriza-
tion, presence and extent of mi-
crovascular dysfunction, and 
myocardial fibrosis.
Hypertrophic cardiomyopathy (HCM), the most common inher-ited cardiomyopathy, represents 
one of the most fascinating diseases in 
cardiovascular medicine, attracting the 
interest of physicians, geneticists, and 
scientists worldwide. This disorder is 
characterized by inappropriate myo-
cardial hypertrophy occurring in the 
absence of any detectable cardiac or 
systemic cause, such as aortic steno-
sis arterial hypertension (1). The di-
agnosis requires exclusion of disease 
entities that may lead to inappropriate 
myocardial wall thickening of other 
etiologies, such as infiltrative and met-
abolic storage diseases (the so-called 
phenocopies). Familial transmission is 
found in about 60% of probands and 
generally follows an autosomal-dom-
inant pattern (2). In most patients, 
HCM is caused by mutations in one 
of the genes encoding cardiac sarco-
mere proteins (3); however, many 
other genes have been shown to cause 
rare forms of HCM, including Z-disk 
proteins and mitochondrial genes. Of 
note, disease-causing mutations do 
not account for the great variability 
of phenotypes and clinical profiles ob-
served even within the same families, 
pointing to additional and poorly un-
derstood genetic, epigenetic, and envi-
ronmental factors as critical modifiers 
of HCM expression (4). Adding to this 
complexity is the observation that mu-
tations in the same sarcomere protein 
genes may result in dilated, restrictive, 
and noncompaction phenotypes rather 
than HCM.
As shown in population-based 
studies, most HCM patients seem to 
remain asymptomatic and undiag-
nosed in the community and have nor-
mal life expectancy. Not infrequently, 
however, the presence of HCM may be 
detected on an electrocardiogram or 
at echocardiography during pre-par-
ticipation athletic screening or routine 
medical check-ups. Conversely, symp-
tomatic patients will actively seek 
medical attention due to palpitations, 
syncope, exertional dyspnea (with or 
without chest pain), systemic throm-
boembolism, and stroke (5). These 
symptoms are caused by the inter-
play of features such as intraventric-
ular obstruction, microvascular ische-
mia, diastolic heart failure, sustained 
supraventricular arrhythmias, and 
recurrent nonsustained ventricular 
arrhythmias. Rarely, HCM may pre-
sent with cardiac arrest and sudden 
cardiac death (SCD). To date, HCM 
represents the most commonly iden-
tified cause of premature SCD due to 
malignant ventricular arrhythmias in 
young individuals and athletes (2,5).
Historical Perspective: How Imaging 
Has Changed Our Perception of the 
Disease
Though several reports suggest that 
HCM had already been recognized cen-
turies ago, it was not until the late 1950s 
that the disease was brought to the 
attention of the international medical 
community (6). Brock, Morrow et al, 
and Braunwald et al reported functional 
obstruction of the left ventricle (LV) oc-
curring at the LV outflow tract, simulat-
ing aortic stenosis, an entity defined as 
“idiopathic hypertrophic subaortic ste-
nosis” (7–9). Nearly at the same time, 
Teare (10) reported asymmetric hyper-
trophy of the heart involving the inter-
ventricular septum and anterior LV wall 
in young adults who died suddenly, half 
of whom were asymptomatic prior to 
their death. Interestingly, the patho-
logic picture was virtually the same in 
all these individuals, one of bizarre and 
disorganized arrangement of muscle 
bundles (the so-called myocardial dis-
array) with hypertrophy of individual 
muscle fibers and their nuclei (Fig 1). 
Not infrequently, extensive replacement 
fibrosis was found, mainly at the cen-
ter of the hypertrophied myocardium, 
deemed to be postischemic in origin. 
At the same time, the genetic nature of 
HCM was suspected, based on the au-
tosomal dominant inheritance pattern 
in the family of one of the victims (11).
Historically, any attempt toward 
the ultimate definition of HCM has 
been hampered by the fact that, rather 
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Figure 1
Figure 1: Phenotypic heterogeneity of HCM beyond LV hypertrophy. (a) Transthoracic echocardiogram (parasternal long-axis view) shows important thickening of 
the basal and mid-part of the interventricular septum (∗). At histologic examination, (b) myocardial disarray (hematoxylin-eosin; magnification, 310), (c) myocardial 
replacement fibrosis (trichromic stain; magnification, 310), and (d) severe remodeling of the intramural arterioles (hematoxylin-eosin; magnification, 310) prevail. 
(e) At transesophageal echocardiography, LV outflow tract obstruction with secondary mitral regurgitation is often present in HCM patients. (f) Midventricular HCM 
may cause the formation of an apical LV aneurysm (arrows).
than a single well-defined entity, the 
disease seemed to include a spectrum 
of conditions. This led to an impressive 
proliferation in disease nomenclature 
(4), many of which were based on the 
concept of “stenosis” or “obstruction.” 
The term hypertrophic cardiomyopathy 
ultimately gained universal consensus, 
following recognition that only a subset 
of patients have an obstructive form of 
the disease. Genotype-positive, pheno-
type-negative individuals, however, be-
long to the spectrum of HCM despite the 
absence of hypertrophy, raising further 
potential controversy over the issue of 
“nonhypertrophic” HCM.
The pioneering studies from the 
1960s marked the beginning of exten-
sive clinical, pathologic, genetic, and 
molecular research into this highly 
complex disease. Owing to these efforts, 
our perception of HCM has gradually 
shifted from that of a rare and malig-
nant disease to the current perspec-
tive of a relatively common and often 
favorable condition, compatible with 
normal life expectancy (4). This par-
adigm shift is largely due to improved 
knowledge of the natural evolution of 
HCM in unselected, community-based 
patient populations, as compared with 
the highly selected early cohorts seen 
at international tertiary referral centers 
(4,5). Because an unfavorable outcome 
is relatively uncommon in HCM popula-
tions, early recognition and risk stratifi-
cation are both challenging and crucial 
in identifying those patients who may 
benefit from aggressive management, 
while allowing cautious reassurance in 
the remainder (5).
At the time of the earliest HCM 
investigations, the only means of as-
sessing pathophysiology in vivo was LV 
catheterization. In the absence of direct 
visualization of the LV and mitral appa-
ratus, hemodynamic studies allowed the 
identification of subaortic gradients but 
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Figure 2
Figure 2: Severe form of asymmetric septal HCM in 20-year-old man. Steady-state free precession (SSFP) images (repetition time msec/echo time msec, 2.7/1.4; 
55° flip angle; 1.4 3 2.0-mm in-plane resolution) are shown (a) in horizontal long-axis, (b) in midventricular short-axis, and (c) along the LV outflow tract. The loca-
tion and extent of hypertrophy as well as the effect of the hypertrophied myocardium on the LV outflow tract can be well appreciated by using cine imaging in several 
imaging planes. The maximal thickness of the ventricular septum is 43 mm. Note the extension of hypertrophy toward the right ventricular apex and free wall.
not of their cause, which remained an 
enigma until the advent of echocardiog-
raphy in the late 1960s. Echocardiogra-
phy has proven critical in developing a 
comprehensive understanding of HCM, 
by allowing recognition of its true prev-
alence, phenotypic heterogeneity, and 
pathophysiologic implications. The de-
scription of systolic anterior motion of 
the mitral leaflets finally unraveled the 
mystery of LV outflow tract obstruction 
that had lasted over a decade (12,13). 
It also explained the impressive results 
of surgical myectomy—an operation in-
troduced as a leap of faith, well before 
the cause of obstruction was discovered 
(14). Subsequently, echocardiography 
demonstrated that most HCM patients 
develop outflow obstruction either in 
resting conditions or with exercise 
(15,16) and revealed a spectrum of 
HCM manifestations beyond LV hyper-
trophy, ranging from mitral valve abnor-
malities to apical aneurysms (17,18). 
From an epidemiologic perspective, 
echocardiography has led to an accu-
rate estimate of HCM prevalence in the 
general population (around 1:500) and 
appropriate screening of HCM family 
members (19). In the clinical setting, 
transthoracic echocardiography rep-
resents the reference standard for se-
rial evaluation of time-related changes 
in clinical and hemodynamic status, 
identification of HCM-related complica-
tions, and assessment of pharmacologic 
and invasive treatment options.
Several noninvasive imaging modal-
ities have been utilized in HCM aside 
from echocardiography. Thallium-201 
single-photon emission computed to-
mography (SPECT) and positron emis-
sion tomography (PET) have been key 
in demonstrating myocardial perfusion 
defects and blunted coronary reserve, 
subtended by marked anatomic remod-
eling of the coronary microcirculation 
(20–22). Computed tomography (CT), 
currently performed with multidetector 
technology, is particularly helpful in vi-
sualizing subtle morphologic abnormal-
ities of the HCM phenotype, such as 
myocardial crypts and coronary artery 
abnormalities including myocardial 
bridging, anomalous origin, or superim-
posed atherosclerotic disease (23,24). 
Last but not least, since its introduction 
in the mid-1980s, cardiac magnetic res-
onance (MR) imaging has now evolved 
into a multiparametric imaging modal-
ity allowing a truly comprehensive pa-
tient- and disease-tailored appraisal of 
HCM, providing information on major 
areas of interest including cardiac phe-
notype, its functional and hemodynamic 
characterization, presence and extent 
of microvascular dysfunction, and myo-
cardial fibrosis (Fig 2) (25).
Characterization of Phenotype and 
Diagnosis
Clinical Aspects
The “classic” HCM phenotype is that of 
a hypertrophied, nondilated LV (Figs 
1, 2). LV hypertrophy typically arises 
during adolescence and is usually com-
plete by young adulthood, though on-
set of phenotype may occur at virtually 
any age, including in utero and older 
than 60 years (26). When investigat-
ing a patient with a potential diagno-
sis of HCM, however, it is important to 
consider that the phenotypic spectrum 
expands well beyond the mere pres-
ence of LV hypertrophy, to include an 
array of morphofunctional manifesta-
tions such as abnormalities of papillary 
muscles and mitral apparatus, deep 
myocardial crypts, myocardial bridging 
of coronary arteries, left atrial remod-
eling, areas of LV noncompaction, api-
cal aneurysms, LV outflow obstruction, 
microvascular dysfunction, and myo-
cardial fibrosis (Tables 1, 2). Further-
more, in 5%–15% of patients adverse 
LV remodeling occurs with progressive 
dilation, wall thinning, dysfunction, and 
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Table 1
The Different Manifestations and Outcomes of HCM: From Genotype-Positive/Phenotype-Negative to Refractory Heart Failure
Phenotype Prevalence Phenotypic Expression
LV Ejection  
Fraction
LGE*
Risk of SCDPrevalence
Percentage  
of LV Mass Location
Nonhypertrophic  
phase
Myocardial wall thickness: normal/borderline increase 
Deep myocardial crypts 
Accessory apical-basal muscle bundle 
Abnormal mitral valve/papillary muscles 
Microvascular dysfunction: ? 
Interstitial myocardial fibrosis: ?
Normal Rare/absent Limited Midwall Exceptional
“Classic”  
phenotype
75% Myocardial hypertrophy: overt 
LV obstruction (70%) 
Left atrium dilatation: mild to moderate, severe when  
 LV outflow tract obstruction present 
Microvascular dysfunction 
Myocardial bridging
Increased 
 (. 65%)
Common 
 (6 40%)
2% (Median) Midwall Low (0.5%–
1%/year)
Adverse  
remodeling
15% Myocardial hypertrophy: evident but progressive  
 thinning may occur 
LV obstruction: less common, loss of prior obstruction 
Left atrium dilatation: moderate/severe 
Microvascular dysfunction: moderate to severe 
Apical aneurysm
50%–65% Common  
 (. 50%)
10%–15% Midwall/
transmural
Probably  
 intermediate
“End-stage”  
HCM
65% “Dilated – hypokinetic” form: 
 LV obstruction: absent 
 Frequent LV wall thinning 
 Severe microvascular dysfunction 
 May mimic dilated cardiomyopathy 
“Restrictive – hypokinetic” form: 
 Small LV 
 Severe biatrial dilatation 
 May mimic restrictive cardiomyopathy
,50% Common  
 (75%–100%)
.25% Midwall/  
 transmural  
 “infarct”-like
High (10%/
year)
* LGE = late gadolinium enhancement.
Table 2
From Pathophysiology to Clinical Decision Making in HCM: Insights from MR Imaging
Anatomic Substrates
Morphofunctional 
Correlates Clinical End Points
Relevant 
Indications
Myocardial hypertrophy* Atrial dilatation* Atrial fibrillation Anticoagulation
Myofiber disarray Adverse LV remodeling* Stroke-thrombo-embolic events Ablation of atrial fibrillation
Replacement fibrosis* LV outflow tract /midventricular  
 obstruction*
SCD Implantable cardioverter defibrillator  
 implantation
Microvascular remodeling Mitral regurgitation* Heart failure Surgical myectomy/alcohol ablation
Interstitial fibrosis† Diastolic dysfunction† “End-stage” HCM Antiremodeling pharmacological therapy
Mitral (sub)valvar abnormalities* Microvascular hypoperfusion† Heart transplant
Myocardial crypts* Apical aneurysm*
Accessory apical-basal muscle bundle* Arrhythmogenesis
Myocardial bridging†
Noncompaction*
* Routinely assessed at MR imaging.
† Potential role of MR imaging.
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evolution toward overt heart failure, a 
phenomenon called “end-stage” HCM, 
resembling dilated or, more frequently, 
restrictive cardiomyopathy (Table 1) 
(27–29).
Each of these elements should be 
carefully sought and considered to es-
tablish a diagnosis and characterize 
the severity of HCM disease expression 
(Table 2).
In probands, HCM is considered 
present when maximum LV wall thick-
ness is 15 mm or greater (or the equiv-
alent relative to the body surface area 
in children) (30). In a minority of pa-
tients, the increase in wall thickness 
can be extreme, exceeding 30 mm (Fig 
2). Borderline increases in wall thick-
ness (ie, 12–14 mm) may be difficult 
to interpret, although a positive family 
history of HCM suggests this diagnosis 
in this gray zone (4). Most often, the 
distribution of hypertrophy is asym-
metric and segmental, while diffuse, 
concentric forms of HCM represent a 
minority (about 5%) (4,30). Notably, in 
about 20% of HCM patients LV mass 
index values are normal at MR imag-
ing (31). In 70% of patients the hy-
pertrophied regions involve the basal 
segments of the anterior ventricular 
septum and anterior wall (32). Other 
less frequent locations are the mid- and 
lower portion of the ventricular septum 
often extending to the inferior wall, 
the anterolateral wall, and the apex. 
Hypertrophy of the papillary muscles 
and right ventricle often concurs (33). 
Exploiting the three-dimensional (3D) 
features of cine MR imaging, it was 
shown that in most HCM patients the 
hypertrophied myocardium follows a 
longitudinal pattern along a spiral tra-
jectory in a counter clockwise direc-
tion from the base to the apex of the 
LV (Fig 3, Movie 1 [online]) (34). The 
magnitude of spiraling ranged from 
minimal—following an almost straight 
trajectory—to marked, covering nearly 
the entire circumference of the LV.
Apical HCM accounts for less than 
10% of HCM patients, although it is 
more prevalent in Japanese cohorts, 
typically associated with giant inverted 
anterolateral T-waves on the electrocar-
diogram (Fig 4, Movie 2 [online]) (35). 
Furthermore, apical extension of LV hy-
pertrophy can be found in 10% of pa-
tients with classic septal HCM, suggest-
ing that both phenotypic expressions 
may coexist (34). Traditionally, the same 
cutoff value (15 mm) is used to diag-
nose apical HCM (35), although a lower 
cutoff is probably advisable, given that 
the myocardium is normally thinner at 
this level (36). Apical HCM is generally 
not associated with outflow obstruction 
and is clinically well tolerated. However, 
when severe, it can determine extensive 
cavity obliteration and restrictive path-
ophysiology, causing severe congestive 
symptoms. Severe midapical forms of 
HCM can cause dynamic obstruction at 
the midventricular level. Occasionally, 
these patients develop a noncontractile 
apical aneurysm (present in about 2% of 
consecutive HCM patients) which por-
tends increased arrhythmic and cardio-
embolic risk (Table 2) (37).
Abnormalities in morphology and 
function of the mitral valve apparatus 
are often seen in HCM patients (38), the 
most striking being a marked elongation 
of both mitral leaflets. These abnormal-
ities may also be present in genotype-
positive family members with none of 
the other phenotypic expressions of 
HCM (Table 1). Mitral leaflet elongation 
Figure 3
Figure 3: Three-dimensional spread of hypertrophy following a counter clockwise spiral in a 38-year-old man 
with asymmetric septal HCM. (a–c) Short-axis SSFP images (2.7/1.4, 55° flip angle, 1.4 3 2.0-mm in-plane 
resolution) at end-diastole at three levels from LV base (a) to apex (c) allow one to appreciate the spiral nature 
of the hypertrophied myocardium (arrows). (d) Volume-rendered 3D image of the heart (anterior view). The 
hypertrophied myocardium is in red. (Reprinted, with permission, from reference 34.) See Movie 1 (online).
REVIEW: MR Imaging in Hypertrophic Cardiomyopathy Bogaert and Olivotto
Radiology: Volume 273: Number 2—November 2014 n radiology.rsna.org 335
is considered an important determinant 
of dynamic obstruction (Table 2). Sub-
valvular abnormalities include hypertro-
phy and variation of the papillary muscle 
in appearance (eg, bifid), number, and 
implantation (ie, short chordae or direct 
papillary muscle insertion into the mitral 
leaflets) (Fig 5). Anteroapical displace-
ment of the anterolateral papillary mus-
cle may contribute to the severity of LV 
outflow obstruction (39,40).
Deep muscular clefts or crypts (ie, 
narrow, blood-filled myocardial invagi-
nations) usually located in the basal in-
feroseptal LV wall have been frequently 
reported in HCM patients (41). These 
are considered among its distinctive 
morphologic expressions, occurring 
both in patients and in genotype-positive 
family members (Table 2) (42,43). Like-
wise, regions of noncompaction (ie, ex-
cessive myocardial trabeculations), most 
typically at the inferior and lateral apical 
segments of the LV, are increasingly re-
ported in HCM patients. While the iden-
tification of these areas bears doubtful 
(if any) clinical importance, noncompac-
tion may represent a marker of genetic 
transmission in family members without 
hypertrophy (Table 2).
Finally, myocardial bridging of the 
left anterior descending coronary artery 
belongs to the phenotypic spectrum 
of HCM (Table 2). Early studies have 
reported an association between coro-
nary bridging and risk of SCD, partic-
ularly in children. However, subsequent 
studies in larger cohorts have shown 
that bridging is in most instances a be-
nign feature (24,44). Only when severe 
and extensive, myocardial bridging may 
be the cause of symptoms and ventricu-
lar arrhythmias in young HCM patients, 
whereas its clinical relevance appears 
questionable in adult patients with no 
or mild symptoms.
Role of MR Imaging in Morphofunctional 
Characterization of HCM
There is an emerging role for MR im-
aging in the evaluation of HCM phe-
notype and its differentiation from 
phenocopies (Table 3) (32,45,46). MR 
imaging is the most accurate technique 
to obtain correct measurements of 
maximal wall thickness in echocardio-
graphically “difficult” regions of the LV, 
increasing the diagnostic yield by iden-
tifying subtle forms of myocardial hy-
pertrophy (Fig 6) (47). Furthermore, 
MR may be helpful in risk stratification 
by identifying massive LV hypertro-
phy or extensive areas of myocardial 
fibrosis heralding disease progression 
(45). Though adequate assessment can 
be achieved by using black-blood fast 
T1-weighted spin-echo MR imaging, 
bright-blood balanced SSFP cine MR 
has the advantage of providing dynamic 
images with high spatial and contrast 
resolution, thereby fusing morphologic 
and functional assessment into one 
MR sequence (Fig 2). Dynamic cine 
imaging allows assessment of myo-
cardial motion patterns, visualization 
of hemodynamic abnormalities (such 
as flow void due to acceleration and/
or turbulence by LV outflow tract ob-
struction, midventricular gradients, or 
mitral regurgitation), and calculation 
of ventricular volumes and myocardial 
mass. Use of 3D bright-blood SSFP 
imaging using a respiratory navigator 
pulse provides high-spatial-resolution 
morphologic images of the coronary 
artery anatomy and papillary muscle 
abnormalities (46).
At present there are no guidelines 
identifying standardized MR imaging 
planes in HCM patients. To assess the 
Figure 4
Figure 4: Apical HCM in a 54-year-old man. Cine 
SSFP MR image (2.7/1.4, 55° flip angle, 1.4 3 2.0-
mm in-plane resolution) in horizontal long-axis plane 
at end-diastole is shown. The LV apex is clearly 
hypertrophied (maximal wall thickness, 18 mm). See 
Movie 2 (online).
Figure 5
Figure 5: Asymmetric septal HCM in a 24-year-old asymptomatic woman with septal hypertrophy at 
routine echocardiography and electrocardiography. On (a) midventricular short-axis cine SSFP MR image 
(2.7/1.4, 55° flip angle, 1.4 3 2.0-mm in-plane resolution) and (b) LGE MR image (4.3/1.3, 260-
msec inversion time), the focal thickening of the anteroseptal LV wall can be well appreciated (maximal 
thickness, 19 mm). Note concomitant hypertrophy of the adjacent right ventricular trabeculations (arrow, 
a) and the anterior papillary muscle (arrowhead, a), which is medially displaced. Measurements of 
myocardial wall thickness should not include these paraseptal structures. Following contrast agent admin-
istration, subepicardial enhancement is present in the thickened LV wall (arrow, b).
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spatial extent of hypertrophy, we rec-
ommend the acquisition of a complete 
set of contiguous short-axis images 
and at least one vertical and one hor-
izontal long-axis image. Important ad-
ditional planes include those along the 
LV outflow tract (Fig 2). Apical HCM, 
sometimes difficult to assess with 
echocardiography because of near-field 
problems of the echo probe, is opti-
mally visualized with MR. Even when 
mild, apical hypertrophy should be 
considered present when the normal 
morphologic thinning of the LV myo-
cardial wall toward the apex is absent 
(Fig 4). When the acoustic window is 
suboptimal, the differential diagnosis 
between apical HCM and isolated LV 
noncompaction may be challenging 
with echocardiography, and MR im-
aging may be decisive in reaching the 
correct diagnosis.
When the HCM phenotype is fully 
expressed, echocardiography gener-
ally allows a reliable and unequivocal 
diagnosis. Occasionally, however, the 
differential diagnosis with phenocop-
ies may be challenging. MR imaging 
has evolved into an excellent tool al-
lowing further characterization of 
“thick-walled” ventricles (Table 4). In 
this case however, bright-blood cine 
MR imaging often does not suffice, 
necessitating a more comprehensive 
approach including LGE and velocity-
encoded cine MR imaging (Table 3).
Differential Diagnosis
Physiologic remodeling resulting from 
regular and intensive exercise, gener-
ally known as “athlete’s heart,” may 
cause LV hypertrophy. However, LV wall 
thickness increase is uncommon (even 
in elite athletes), concentric, usually 
mild, and paralleled by a proportional 
increase in volume of both ventricles 
(Table 4) (48,49). End-diastolic wall 
thickness does not generally exceed 
13 mm in male and 11 mm in female 
athletes. Thickness values greater than 
15 mm should be considered definitely 
abnormal (50). In the “grey zone” of LV 
wall thickness (.12 mm to 15 mm), a 
correct diagnosis is as difficult as it is 
important, in that it may prevent dis-
ease-related complications in the pres-
ence of true HCM or allow continuation 
of a normal life, including competitive 
activities, when HCM can be excluded 
(51). Decision making in this gray area 
can never be based on a single piece 
of information, and it involves consid-
eration of a number of additional ele-
ments such as the electrocardiogra-
phy pattern, diastolic indexes, family 
history, genetic testing, and response 
to detraining. Of note, the effects of 
detraining on LV hypertrophy can be 
Table 3
Overview of Standard, Optional, and Research MR Sequences to Study HCM
MR Sequence Purpose
Standard
 Scout views Determination of cardiac image planes
 SSFP cine imaging LV/right ventricle volumes, ejection fraction, and mass 
Myocardial wall thickness 
Regional function (motion/thickening) 
Geometric pattern of hypertrophy 
Calculation of LV outflow tract diameter/area 
Mitral regurgitation (visual analysis) 
Myocardial crypts 
Left atrial size and function
 LGE imaging Myocardial replacement fibrosis 
Evaluation of effects of therapy (scar tissue) 
Thrombus formation in left atrial appendage (atrial fibrillation)
 Velocity-encoded cine  
 imaging
Hemodynamic consequences of obstruction (gradient calculation 
Quantification of mitral regurgitant volume/fraction 
Diastolic (dys)-function (mitral inflow/pulmonary vein flow)
Optional
 T1-weighted fast spin-echo  
 imaging
Morphologic evaluation (if insufficient information with cine imaging)
 3D SSFP imaging Detailed anatomic information (eg, papillary muscle abnormalities/crypts)
 T1 mapping Quantification of extracellular volume reflecting myocardial interstitial  
 fibrosis
 T2-weighted imaging/T2  
 mapping
Myocardial edema (eg, acute ischemia)
 Rest/stress perfusion  
 imaging
Microvascular function 
Hemodynamic significant coronary artery stenoses
 MR tagging Myocardial deformation analysis (two-dimensional/3D)
 3D contrast-enhanced  
 MR angiography
Pulmonary vein anatomy (preablation vein imaging in atrial fibrillation  
 patients)
Research
 Diffusion imaging Myofiber disarray
 MR spectroscopy Metabolic spectra
Figure 6
Figure 6: Focal HCM in a 47-year-old woman 
with family history of HCM. Horizontal long-axis 
cine SSFP MR image (2.7/1.4, 55° flip angle, 
1.4 3 2.0-mm in-plane resolution) shows focal 
thickening of the apical part of the ventricular 
septum (arrow) extending to the adjacent RV free 
wall (arrowheads).
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accurately assessed by means of serial 
cine MR imaging.
Increased LV afterload due to 
systemic arterial hypertension or aor-
tic stenosis may simulate HCM. Aortic 
stenosis is generally easy to rule out 
with echocardiography; in complex 
cases, however, the presence and he-
modynamic consequences of aortic 
stenosis can be assessed with MR by a 
combination of cine imaging and veloc-
ity-encoded imaging, enabling accurate 
measurement of the aortic valve orifice 
and transvalvular pressure gradient 
(52). Differentiating HCM from hyper-
tensive cardiomyopathy may be more 
challenging, particularly in hypertensive 
patients manifesting asymmetric LV hy-
pertrophy. Of note, while the spectrum 
of geometric adaptations in hyperten-
sive cardiomyopathy is complex, most 
untreated patients with systemic arte-
rial hypertension have normal LV mass 
and wall thickness, while “typical” hy-
pertensive concentric hypertrophy oc-
curs only in a minority (53).
LV noncompaction belongs to the 
phenotypic spectrum of mutations in 
genes encoding proteins of the cardiac 
sarcomere (Table 2). Of note, the pri-
mary nature of isolated LV noncom-
paction as a distinct cardiomyopathy is 
currently being challenged as aspects of 
noncompaction can be observed in vir-
tually all forms of genetic heart disease, 
as well as in congenital malformations 
(3,54) and athletes (55). MR is increas-
ingly used to investigate patients with 
suspected LV noncompaction, although 
the lack of reliable MR criteria for diag-
nosis leads to a substantial risk of over-
estimating its prevalence (56,57) (Table 
4). Isolated noncompaction may mimic 
apical HCM when particularly severe 
and occurring at the midapical LV level, 
where it may be hard to recognize by 
using echocardiography.
Cardiac amyloidosis is a rare but im-
portant phenocopy of HCM. Cardiac in-
volvement may be the presenting feature 
or may be discovered while investigating 
a patient manifesting noncardiac features 
of the disease. Prognosis in these patients 
is driven by the cause of amyloidosis and 
by the severity of cardiac involvement 
(58). Diffuse amyloid deposition involves 
left and right ventricular myocardium in 
a concentric pattern and extends to the 
valve leaflets, atrial walls, and septum; 
mild concentric pericardial effusion may 
coexist. LV systolic function may be rel-
atively spared (although often reduced), 
whereas severe diastolic dysfunction 
with restrictive pathophysiology is the 
rule in advanced disease. LGE imaging 
is extremely helpful in differentiating 
cardiac amyloidosis from HCM, by re-
vealing characteristic patterns of myo-
cardial enhancement, including global, 
subendocardial, less often patchy or dif-
fuse LGE distribution within the LV (59). 
These patterns are determined by the 
distribution and severity of amyloid depo-
sition and are related to outcome (Fig 7) 
(60,61). In cardiac amyloidosis, altered 
gadolinium kinetics in the blood and myo-
cardium—that is, diffuse LGE associated 
with increased clearance of gadolinium 
from the blood pool, producing small dif-
ferences in T1 relaxation time between 
blood and myocardium—causes the ven-
tricular cavity to appear dark while the 
myocardium remains bright irrespective 
of the inversion time used. Thus, if the 
administration as well as the dosage of 
gadolinium-based contrast medium are 
correct, this pattern should immediately 
raise the suspicion of amyloid infiltration 
of the LV, particularly in the presence 
unexplained myocardial hypertrophy. Re-
cently, non–contrast-enhanced T1 map-
ping and equilibrium contrast enhance-
ment MR imaging have been proposed as 
appealing noninvasive techniques to diag-
nose and to quantify the amyloid burden 
of the heart, potentially predicting out-
come (59,62).
Cardiomyopathies associated with 
metabolic storage diseases (eg, An-
derson-Fabry, Pompe, Gaucher, and 
Neimann-Pick disease) represent rare, 
genetically determined phenocopies, 
characterized by a variety of cardiac 
signs and symptoms including LV hy-
pertrophy, diastolic dysfunction, ar-
rhythmias, microvascular ischemia, 
and heart failure. MR imaging may be 
useful at various stages in establishing 
the diagnosis and evaluating prognosis 
and disease progression, as well as in 
monitoring the effects of management, 
including enzyme-replacement therapy. 
About half of Anderson-Fabry patients 
show areas of LGE in the LV inferolat-
eral wall reflecting focal scarring, which 
has been proposed as a substrate for 
arrhythmias and SCD (63). Intramyo-
cardial glycosphingolipid accumulation 
may be measured with non–contrast-
enhanced T1 mapping, showing a 
Table 4
Differential Diagnosis in LV Hypertrophy
Morphologic Pattern Differential Diagnosis Useful Clues (Suggesting HCM)
Mild LV hypertrophy Athlete’s heart Small/normal size LV 
Elongated mitral valve/SAM 
Myocardial crypts 
Accessory apical-basal muscle bundle 
Presence of LGE (rarely present)
Mild-moderate  
LV hypertrophy
Hypertensive heart disease 
Aortic stenosis
Normal aortic root 
Normal aortic valve 
Elongated mitral valve/SAM 
Extensive/patchy LGE
Severe LV hypertrophy Amyloidosis 
Other storage diseases
Spared atrial walls and septum 
Lack of pericardial effusion 
Septal as opposed to endocardial LGE 
Elongated mitral valve/SAM 
Preserved systolic function
Apical LV hypertrophy LV noncompaction Thickened apical myocardium (as opposed to  
 extensive trabeculations)
Note.—SAM = systolic anterior motion.
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substantial decrease in T1 relaxation 
values and allowing differentiation with 
other diseases such as HCM, amyloid-
osis, and hypertensive disease (64).
Endomyocardial disease (ie, Löf-
fler endocarditis and endomyocardial 
disease) is a rare form of restrictive 
cardiomyopathy that may simulate 
HCM. MR imaging enables depiction 
of the fibrous endocardial thicken-
ing, myocardial inflammation, apical 
or subvalvular obliteration, chordal 
deformation with valvular regur-
gitation, thrombus formation, and 
restrictive LV physiology (Fig 8). 
MR is particularly helpful in differenti-
ating this entity from apical HCM and 
LV noncompaction (65). Finally, rare 
HCM phenocopies include primary and 
secondary cardiac tumors. In particu-
lar, cardiac fibromas and hemangiomas 
occur often intramurally and, when lo-
cated in the anterior LV wall and ven-
tricular septum, may simulate HCM. 
Cardiac metastases are more common 
than primary tumors and are usually 
found in patients with disseminated 
neoplasms. With use of comprehensive 
MR imaging, the differential diagnosis 
with HCM is usually straightforward.
Dynamic LV Outflow Tract Obstruction
Clinical Aspects
LV outflow tract obstruction is such a vis-
ible component of HCM that the disease 
has long been termed “hypertrophic ob-
structive cardiomyopathy (or HOCM),” 
assuming that all patients developed 
subaortic gradients related to systolic an-
terior motion and mitral septal contact 
(66). Large echocardiographic studies 
have later disproved this concept in pa-
tients at rest, most of whom appear to 
have nonobstructive disease. However, 
exercise echocardiography has recently 
reaffirmed the initial view, that is, that 
HCM is largely an obstructive disease, 
because of the high prevalence of provo-
cable gradients on effort. A peak instan-
taneous outflow gradient of 30 mm Hg or 
greater under basal conditions or of 50 
mm Hg or greater with exercise defines 
clinically significant dynamic obstruction, 
typically occurring during late systole 
and ranging from mild degrees of imped-
ance to severe obstruction with gradients 
greater than 100 mm Hg. Besides the 
common subaortic obstruction, intraven-
tricular gradients may be observed at the 
midventricular level and, rarely, at the 
right ventricular outflow tract.
Dynamic obstruction is a common 
cause of dyspnea, angina, and syn-
cope on effort and is associated with 
increased risk of heart failure–related 
death (Table 2) (67). The pathophysiol-
ogy of mitral leaflet systolic anterior mo-
tion is complex (38,39). During systole, 
abnormal acceleration and misdirection 
of the flow toward the outflow create 
“drag forces,” which push the mitral 
leaflets anteriorly, causing septal contact 
and impedance to flow, as well as loss 
of coaptation and mitral regurgitation 
(Fig 9, Movie 3 [online]). The degree of 
mitral regurgitation may be moderate 
to severe, often with marked increase 
during exercise, ultimately promoting 
left atrial enlargement and atrial fibril-
lation. Because of a number of patho-
physiologic determinants, outflow gra-
dients may occur also in patients with 
minimal or no hypertrophy (66). Dy-
namic obstruction is initially managed 
medically, by using negative inotropes 
such as beta-blockers and/or disopyra-
mide. However, when severe and asso-
ciated with drug-refractory symptoms, 
invasive treatment options such as sur-
gical myectomy or percutaneous alcohol 
ablation become necessary (68).
MR Imaging of LV Outflow Tract 
Obstruction
Echocardiography remains the tech-
nique of choice to rapidly, accurately, 
and serially evaluate the presence and 
hemodynamic impact of dynamic ob-
struction. However, MR imaging can 
provide valuable additional informa-
tion regarding its site, mechanism, and 
potential management. For example, 
surgical planning may benefit from the 
superb anatomic detail of the mitral 
valve, subvalvar apparatus, and outflow 
tract offered by MR imaging. Longitu-
dinal and perpendicular cine imaging 
through the LV outflow tract allows op-
timal visualization of systolic anterior 
motion and of the signal void caused 
by flow acceleration and/or turbulence 
at this level, as well as accurate measure-
ment of diameter and/or area changes 
of the outflow tract over the cardiac cy-
cle (Fig 9). An outflow tract of less than 
Figure 7
Figure 7: Cardiac amyloidosis in a 71-year-old 
woman with diastolic heart failure and nonsustained 
ventricular tachycardia at presentation. Midventricu-
lar short-axis LGE MR image (4.3/1.3, 270-msec 
inversion time) shows concentric LV hypertrophy with 
septal wall thickness (23 mm), decreased LV ejection 
fraction (38%), and increased LV mass (262 g). 
Marked, inhomogeneous enhancement is seen in both 
ventricles following contrast agent administration.
Figure 8
Figure 8: Endomyocardial disease in a 78-year-old 
woman with hypereosinophilia at presentation. Hor-
izontal long-axis cine SSFP MR image (2.7/1.4, 55° 
flip angle, 1.4 3 2.0-mm in-plane resolution) dem-
onstrates thickening and deformation of LV apex with 
cavity obliteration. The papillary muscles are involved 
in the inflammatory fibrotic process (arrow). (Image 
courtesy of Ilse Crevits, MD, Roeselare, Belgium.)
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2.7 cm2 in systole measured by using 
MR imaging yielded a 100% sensitivity 
and specificity to differentiate obstruc-
tive (including latent forms) from non-
obstructive HCM (69). In patients with 
severe midventricular and/or RV outflow 
tract obstruction, MR images provide 
critical anatomic details, instrumental 
to planning complex surgery. The com-
bination of cine and velocity-encoded 
MR imaging allows direct measurement 
of outflow tract gradients and quantifi-
cation of concomitant mitral regurgita-
tion (Table 2, Fig 9) (52). However, to 
date, MR remains markedly inferior to 
Doppler echocardiography in the evalu-
ation of flow velocity, particularly when 
assessment of gradients during exercise 
is required.
Microvascular Ischemia, Myocardial 
Fibrosis, and Disease Progression
Clinical Aspects
Autopsy findings in young patients 
with SCD have shown the presence 
of all stages of ischemic damage in 
HCM hearts, ranging from acute le-
sions to old replacement fibrosis (70). 
In the absence of epicardial coronary 
artery disease, ischemic damage is 
subtended by severe microvascular 
remodeling and dysfunction of the 
small intramural arterioles (Table 
2) (71,72). Microvascular ischemia, 
which is most pronounced in—but not 
confined to—the hypertrophied re-
gions, is important in the pathogene-
sis of disease progression and LV dys-
function and is a likely substrate for 
ventricular arrhythmias (22,73,74). 
Of note, microvascular dysfunction 
is more pronounced in gene-positive 
HCM patients compared with those 
without gene mutations (75), suggest-
ing a molecular link between sarco-
mere mutations and microvascular 
remodeling (76).
The magnitude of replacement fi-
brosis is variable and correlates with 
severity of LV remodeling and dysfunc-
tion (76–78). Discrete areas of what 
is supposed to be replacement fibrosis 
are often seen in the midwall (meso-
cardium) of the most hypertrophied 
segments. In the most severe cases, 
transmural fibrotic tissue may occupy 
large portions of the LV wall, giving 
rise to pseudo-infarct patterns and 
the extreme degree of remodeling 
observed in end-stage HCM (Table 1) 
(Fig 10) (Movie 4 [online]) (28,29,79). 
In addition, extensive and transmu-
ral fibrosis consistently occurs in the 
walls of apical aneurysms associated 
with HCM. Replacement fibrosis rep-
resents a different phenomenon from 
the increased extracellular matrix 
commonly seen at the junction of the 
right ventricle with the LV—likely due 
to a different, nonischemic mecha-
nism—and from the fine interstitial 
fibrosis that is diffusely found in HCM 
hearts. The stimulus for interstitial 
fibrosis, reflecting exaggerated acti-
vation of the matrix, may be present 
before the development of cardiac 
hypertrophy in genotype-positive indi-
viduals (80).
Figure 9
Figure 9: Obstructive HCM in a 57-year-old woman with heart failure and atrial fibrillation at presentation: 
(a, b) Cine SSFP MR images (2.7/1.4, 55° flip angle, 1.4 3 2.0-mm in-plane resolution) obtained longitu-
dinally through LV outflow tract at (a) end diastole and (b) early systole depict thickened ventricular septum 
(25 mm) (∗) with narrowing of LV outflow tract (11 mm), systolic anterior motion of anterior mitral valve 
leaflet (arrow, b) coming in apposition with thickened septum, and secondary mild regurgitation with laterally 
oriented jet (arrowheads, b). (c) Velocity-encoded cine MR image perpendicular through the LV outflow tract 
in early systole shows high velocity flow (peak velocity 3.5 m/sec) through the narrowed LV outflow tract 
(arrow). (d) The corresponding flow curve shows complete occlusion of LV outflow tract later in systole. This 
patient was treated by means of alcohol septal ablation. See Movie 3 (online).
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Figure 10
Figure 10: Severe adverse remodeling in a 48-year-old man with HCM and history of SCD in multiple 
family members. (a) Short-axis cine SSFP MR image (2.7/1.4, 55° flip angle, 1.4 3 2.0-mm in-plane 
resolution) and (b) short-axis LGE MR image (4.3/1.3, inversion time 265 msec) show moderately dilated 
(end-diastolic volume, 190 mL) and dysfunctional LV (ejection fraction, 51%). Moderately thickened septum 
(15 mm) (∗) and substantial thinning of the anterior LV wall (arrows, a) show marked enhancement (arrows, 
b). Total area of myocardial enhancement accounted for 23% of the whole LV mass. Note the dilated left 
atrium (21 cm2/m2) and pronounced myocardial trabeculations along the lateral LV wall and apex in Movie 
4 (online). Electrophysiologic testing showed inducible polymorphic ventricular tachycardia and ventricular 
fibrillation. This patient received an implantable cardioverter defibrillator as primary prophylaxis of SCD.
Role of MR Imaging in Assessing 
Microvascular Dysfunction and Fibrosis
Though a great deal of our knowledge 
regarding microvascular ischemia in 
HCM should be credited to the use 
of SPECT and PET, MR imaging has 
now become an interesting alterna-
tive (21,81) because of its superior 
spatial resolution and its capability 
to help identify myocardial fibrosis 
(Table 3) (Fig 11) (Movie 5 [online]) 
(82–84). The perfusion MR sequences 
do not differ from those used in pa-
tients with coronary artery disease 
(eg, saturation-recovery fast gradient-
echo sequence). Studies are typically 
performed at rest and during admin-
istration of a vasodilating agent (eg, 
dipyridamole). Areas of diminished 
myocardial perfusion can be visually 
assessed or semiquantitatively ana-
lyzed (as myocardial perfusion reserve 
ratio); absolute myocardial blood flow 
may also be calculated, but this pro-
cedure remains time consuming and 
largely confined to research purposes.
The introduction of LGE imag-
ing, using two-dimensional or 3D 
inversion-recovery (or alternatively 
phase-sensitive inversion-recovery) 
gradient-echo sequences after admin-
istration of paramagnetic contrast 
agents, led to a paradigm shift in as-
sessing ischemic and nonischemic 
myocardial disease (Figs 2, 5, 11) (85). 
Focal myocardial damage (eg, necro-
sis, replacement fibrosis) as small as 
1 g or less is reliably depicted by LGE, 
while newer T1-mapping techniques 
appear promising in demonstrat-
ing interstitial fibrosis (86,87). To 
date, however, the optimal approach 
for defining and quantifying LGE in 
HCM remains unresolved (88). Image 
contrast following administration of 
gadolinium chelates is largely deter-
mined by the distribution volume (ie, 
the extracellular space) and washout 
characteristics of the contrast agent. 
However, contrary to the homoge-
neous, well-defined enhancement of 
scar tissue in patients with a healed 
myocardial infarction, the hetero-
geneous substrates present in HCM 
(ie, replacement fibrosis, interstitial 
fibrosis, and myofiber disarray) gen-
erate a spectrum of isolated or mul-
tiple patchy patterns of LGE (Figs 2, 
5, 11) (89). Such complexity hampers 
any attempt toward reliable manual 
contouring and requires (semi)-auto-
mated analysis for quantification. By 
using signal intensity in normal (ie, 
nonthickened) myocardium as a refer-
ence, Harrigan et al (90) showed that 
use of 6 or more standard deviations 
from normal myocardial intensity had 
the best correlation with visual assess-
ment. However, validation data from 
29 myectomy specimens from HCM 
patients showed 5 standard deviations 
to have the strongest correlation with 
total (ie, combined interstitial and re-
placement) fibrosis, whereas the best 
correlation with replacement fibrosis 
was obtained at 10 standard devia-
tions (91).
Since the first reports in 2002, 
LGE imaging has gained rapid in-
terest as a potential tool to improve 
risk assessment in HCM patients, in-
dependent of conventional clinical 
predictors (4,92,93). A decade later, 
it is fair to say that several gaps re-
main in our knowledge (94). We have 
learned that LGE is a common finding 
occurring in the majority of HCM pa-
tients (range, 33%–79%) with highly 
variable extent and intensity (83,95) 
and, consistent with prior patho-
logic studies, preferentially localized 
to the midwall of regions with max-
imum LV wall thickness (Table 1) 
(70,96,97). Stress-perfusion defects 
are often found in the same regions 
expressing LGE, although typically 
located in the subendocardial region 
rather than at midwall (Fig 11). How-
ever, LGE may also be observed in 
HCM hearts with no evidence of mi-
crovascular ischemia (82–84).
In clinical practice, LGE imaging 
provides an excellent noninvasive tool 
to identify and monitor disease pro-
gression. Because the classic HCM 
phenotype is associated with pre-
served or increased LV ejection frac-
tion and limited LGE (ie, ,5%), ad-
verse remodeling should be suspected 
when LV ejection fraction is below 
65% and extent of LGE accounts for 
10%–15% or more of the LV mass 
(Table 1) (29). These patients require 
close follow-up to serially evaluate 
the progression of fibrosis and its 
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Figure 11
Figure 11: Extensive microvascular dysfunction in 40-year-old man with asymmetric septal HCM. Images are (a) horizontal long-axis cine SSFP MR image (2.7/1.4, 
55° flip angle, 1.4 3 2.0-mm in-plane resolution), (b) myocardial perfusion MR image during dipyridamole stress, and (c) LGE MR image in midventricular short axis. 
Thickening of the basal and midportions of the ventricular septum (∗) is seen. A large perfusion defect is depicted in the thickened septum during dipyridamole stress 
(arrows, b) which is considerably more extensive than the patchy multifocal areas of late myocardial enhancement (arrows, c). See also Movie 5 (online).
functional consequences. Because of 
the considerable time elapsing from 
initial detection of LGE to overt LV 
impairment, identification of exten-
sive remodeling may be relevant to 
preventive treatment (98).
In a recent study by Todiere et 
al (99), increases in myocardial LGE 
were shown in HCM patients during 
a mean follow-up period of nearly 2 
years (Fig 12), predicting worsening 
clinical status. However, such wide-
spread rapid increase in myocardial fi-
brosis is likely exaggerated by patient 
selection bias. In our experience, a 
similar time-course represents an ex-
ception rather than the rule in HCM 
patients, most of whom exhibit little 
or no change in LGE or clinical status 
in years. Overall, only 1%–2% of new 
patients per year will develop suffi-
ciently severe remodeling to reach 
the end-stage phase of HCM, defined 
as a progressive systolic heart fail-
ure, often coupled with a restrictive 
LV filling pattern, heralding adverse 
outcome (100). Overt dysfunction is 
considered present when LV ejection 
fraction is below 50%—representing 
marked systolic impairment in this 
Figure 12
Figure 12: Progression of myocardial enhancement, reflecting myocardial fibrosis over a period of 8 years in a 57-year-old woman with HCM: (a) baseline study, 
(b) first follow-up study at 5 years, and (c) second follow-up study at 8 years. On these short-axis LGE MR images (4.3/1.3, inversion time ranging between 250 and 
290 msec), increase in size and intensity of myocardial enhancement can be seen in the anteroseptal LV wall (arrow).
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Figure 13
Figure 13: Midventricular HCM with apical aneurysm in 40-year-old man. (a) Horizontal long-axis cine 
SSFP MR image (2.7/1.4, 55° flip angle, 1.4 3 2.0-mm in-plane resolution) and (b) LGE MR image 
(4.3/1.3, inversion time 265 msec) are shown. Note thickening of the midventricular part of the LV (arrows, 
a) with narrowing of LV cavity, apical wall thinning, and aneurysm formation (arrowheads, a). Transmural en-
hancement of the thinned apical wall (arrowheads, b) is seen. (Image courtesy of E. Algheri, MD, Department 
of Cardiovascular Imaging, Prof. Dr. Rémy-Jardin, University Center of Lille, Lille, France.)
Table 5
Risk Factors for SCD
Category Factors
Secondary prevention Cardiac arrest or sustained ventricular tachycardia
Conventional primary  
prevention risk predictors
Family history of SCD due to HCM 
Unexplained recent syncope 
Multiple, repetitive nonsustained ventricular tachycardia (on Holter) 
Abnormal blood pressure response to exercise 
Massive LV hypertrophy (thickness  30 mm) 
Extensive and diffuse LGE
Potential high-risk subsets  
for primary prevention
End-stage phase (LV ejection fraction , 50%) 
LV apical aneurysm and scarring
Potential arbitrators for  
primary prevention
Very early onset (pediatric age) 
Severe LV outflow tract gradient at rest 
Prior alcohol septal ablation 
Multiple sarcomere mutations 
Modifiable: intense competitive sports; coronary artery disease; atrial  
 fibrillation with rapid ventricular conduction
Note.—Adapted, with permission, from reference 4.
disease, and is typically associated 
with extensive LGE (25%–50% of the 
whole LV) (101). Furthermore, pre-
dominance of midwall enhancement is 
lost, and extensive, often transmural 
enhancement predominates, associ-
ated with severe microvascular dys-
function, LV wall thinning, and loss 
of dynamic obstruction (Fig 10, Movie 
4 [online]) (102). Of note, about half 
of the patients with end-stage HCM 
have a small and fibrosed, rather than 
dilated, LV associated with extreme 
diastolic dysfunction and biatrial dila-
tation, resembling restrictive cardio-
myopathy (Table 1).
Sudden Cardiac Death
Clinical Aspects
SCD due to unpredictable ventricular 
tachyarrhythmias and ventricular fibrilla-
tion is the most visible and devastating 
complication of HCM, often occurring in 
asymptomatic individuals younger than 
35 years and in competitive athletes (4). 
Fortunately, it is a rare occurrence, with 
a mean annual rate less than 1% (5). 
The identification of high-risk patients 
has become progressively more relevant 
to clinical practice following large-scale 
introduction of the implantable cardio-
verter defibrillator and is today one of 
the most hotly debated issues in HCM. 
Over the past 50 years, several SCD 
risk factors and potential risk modi-
fiers have been identified from obser-
vational studies, allowing the construc-
tion of algorithms for risk stratification 
(Table 5). With the exception of a previ-
ous history of resuscitated cardiac arrest, 
however, these risk factors have very low 
positive predictive values (, 20%) (5). 
As a consequence, primary prevention of 
SCD remains challenging, and therapeu-
tic strategies are often based on personal 
experience and individual preferences 
rather than solid evidence.
Potentially lethal ventricular ar-
rhythmia in HCM originates from the 
interplay of multiple substrates and 
triggers ranging from microvascular is-
chemia to electrophysiologic remodeling 
of the cardiomyocyte (Table 2). Myofi-
ber disarray, replacement, and inter-
stitial myocardial fibrosis all may bear 
arrhythmogenic potential (4,29). This 
concept is supported by the observa-
tion that clinical examples of advanced 
fibrotic remodeling of the LV, such as 
apical aneurysms and end-stage HCM, 
both identify subsets with markedly in-
creased risk of SCD, warranting aggres-
sive management (Fig 13) (101,103).
Role of MR Imaging
Recently, LGE imaging has been recog-
nized as a potential arbitrator in assess-
ing risk of SCD (104). Several reports 
are consistent in highlighting the asso-
ciation of marked degrees of LGE with 
risk of arrhythmic events. However, 
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these studies were generally based on 
surrogate end points (such as nonsus-
tained ventricular tachycardia) and un-
derpowered to address SCD as an end 
point (96,97,105–107). Furthermore, 
as highlighted by Ismael et al (108), the 
key question is not only whether LGE is 
associated with arrhythmic events, but 
whether it adds independent prognos-
tic value over and above traditional risk 
factors already in use.
Because LGE is common, its mere 
presence or absence is unlikely to have 
any clinical utility, so that the issue 
rather becomes whether its amount and 
extension may be predictive of outcome 
in individual patients. A recent multicen-
ter, prospective study in 1300 consecu-
tive HCM patients followed for more 
than 3 years has shown that extensive 
LGE, occupying 15% or more of whole 
LV myocardium, is an independent pre-
dictor of SCD (109), potentially relevant 
to decision making concerning cardio-
verter defibrillator implantation (Table 
5). Of note, the same magnitude of LGE 
predicted heart failure–related events.
Atrial Fibrillation and Cardioembolic 
Risk
Clinical Aspects
Atrial fibrillation is the most com-
mon complication of HCM, occurring 
in nearly one-fourth of the patients, 
with an annual incidence of 2% (110). 
Predisposing factors include elevated 
LV end-diastolic pressures second-
ary to diastolic dysfunction, mitral 
regurgitation due to systolic anterior 
motion, and a primary myopathic 
process involving the atria (Table 2). 
Marked left atrial remodeling (ie, a 
combination of dilatation and fibrosis) 
generally constitutes the substrate for 
atrial fibrillation (111). True to its def-
inition of “barometer” of the LV, left 
atrial size is an important predictor 
of outcome in HCM, independent of 
atrial fibrillation itself. In one study, 
an echocardiographic left atrial diam-
eter larger than 48 mm (ie, the 75th 
percentile for the whole study group) 
predicted all-cause mortality, cardio-
vascular death, and death related to 
heart failure in HCM patients (112). 
The acute onset of atrial fibrillation, 
often occurring in young HCM pa-
tients, may be life-threatening when 
rapidly conducted to the LV resulting 
in hemodynamic destabilization. Long 
term, HCM patients with atrial fibril-
lation are at increased risk of stroke, 
peripheral embolization, heart failure 
complications, and death. Atrial fibril-
lation occurring in the context of LV 
outflow tract obstruction is poorly tol-
erated by HCM patients.
Role of MR Imaging in Atrial Fibrillation 
and Cardioembolic Risk Stratification
Volumetric determination by means of 
MR imaging is probably the best ap-
proach to assess the degree of atrial re-
modeling, but acquisition and analysis 
may be too time-consuming for daily 
clinical practice. Therefore, one- and 
two-dimensional measurements are 
a valuable alternative, with an area 
greater than 15 cm2/m2 and a trans-
verse diameter greater than 2.8 cm/m2 
in four-chamber view generally used to 
identify left atrial enlargement (Movie 4 
[online]) (113). In patients referred for 
catheter ablation of atrial fibrillation, a 
multiparametric MR imaging approach 
combining cine imaging with contrast-
enhanced MR angiography and imaging 
early following contrast agent adminis-
tration represents a valuable alternative 
to transesophageal echocardiography 
for evaluation of pulmonary vein anat-
omy and exclusion of thrombus in the 
left atrial appendage (Table 3) (114). 
Furthermore, LGE imaging enables 
the assessment of additional arrhyth-
mic substrates and postablation lesions 
within the left atrium (115). Recently, 
ablation procedures in an MR environ-
ment have become feasible in the re-
search setting, potentially opening the 
door for radiation-free procedures in 
HCM patients (116,117).
Planning and Assessing Clinical 
Interventions
Clinical Aspects
In HCM patients with severe drug-re-
fractory symptoms of heart failure in the 
context of dynamic outflow obstruction, 
invasive septal reduction therapies are 
indicated. MR is becoming the tool of 
choice for preprocedural planning and 
assessment of local and remote remod-
eling during follow-up. Surgical septal 
myectomy represents the primary treat-
ment option in these patients, whereas 
catheter-based techniques such as sep-
tal alcohol ablation and coil placement 
or, recently, the mitral clip, should be 
reserved to older patients at unaccept-
able surgical risk (5,118,119). Surgical 
treatment is a low-risk procedure that 
reliably abolishes impedance to LV out-
flow and heart failure symptoms, re-
stores quality of life, and is associated 
with long-term survival similar to that 
of the general population (118,119). 
Moreover, myectomy can be tailored 
to the individual patient by combining 
reconstructive surgery of the papillary 
muscles and mitral valve chordae, as 
well as relief of midventricular and right 
ventricular outflow tract obstruction 
(120). Alcohol septal ablation creates 
a transmural scar at the basal septal 
level, thus enlarging LV outflow tract 
dimensions and relieving obstruction. 
New atrioventricular conduction abnor-
malities are frequent after septal abla-
tion and are related to more extensive 
septal infarctions. Furthermore, the 
procedure is limited by the anatomic 
variability of the coronary tree, relief 
of obstruction is less consistent, and 
the iatrogenic scar has been associated 
with increased risk for life-threatening 
ventricular tachyarrhythmias (118,119).
Role of MR Imaging in Assessing 
Treatment
Multiparametric MR imaging pro-
vides an excellent tool to assess the 
effects of interventional treatment in 
HCM patients. A combination of cine, 
velocity-encoded, and LGE imaging 
provides comprehensive information 
on the LV anatomy, changes in post-
operative morphology (including long-
term reverse remodeling), myocar-
dial substrate (location and extent of 
alcohol-induced scar), hemodynamic 
consequences, and procedure-related 
complications (121–125). Following 
alcohol septal ablation, a transmural 
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Figure 14
Figure 14: Presence of myocardial crypt in 
25-year-old male mutation carrier (MYBPC3) with 
two prior episodes of syncope. Short-axis cine SSFP 
MR image (2.7/1.4, 55° flip angle, 1.4 3 2.0-mm 
in-plane resolution) shows borderline increase in LV 
wall thickness (13 mm) with presence of deep crypt 
in the inferoseptal LV wall (arrowhead). The myocar-
dial crypt can be appreciated on Movie 6 (online).
scar is typically produced in the basal 
septum, which tapers to nontransmu-
ral moving toward the mid-LV and usu-
ally extends into the right ventricular 
side of the septum (126). Moreover, in 
up to 25% of patients, the most proxi-
mal basal septum is spared, because of 
the lack of a septal branch supplying 
that region, accounting for suboptimal 
procedural results. The Amsterdam 
group studied the early and midterm 
effects of septal ablation in HCM pa-
tients (123–125). They observed that 
the induced infarct size correlated with 
gradient reduction and that, following 
relief of obstruction, an overall reduc-
tion in myocardial mass and improve-
ment in systolic function occurred even 
in remote regions of the LV, suggest-
ing regression of secondary hyper-
trophy. In the near future, MR-based 
studies will hopefully provide insights 
regarding the effects of pharmacologic 
treatments aimed at preventing devel-
opment of LV hypertrophy and fibrosis. 
The identification of novel, disease-
specific therapeutic targets, currently 
under investigation, may soon lead 
to the development of pharmacologic 
agents affecting some of the fundamen-
tal mechanisms of HCM pathogenesis 
(29). Trial design will necessarily in-
corporate serial MR evaluation in as-
sessing the efficacy of these drugs.
Evaluation of Genotype-Positive/
Phenotype-Negative Individuals
All mutation carriers are at risk for de-
veloping overt HCM. However, not all 
of them will, and whether (or to what 
extent) hypertrophy will develop remains 
unpredictable based on the individual 
genetic defect. Moreover, routine screen-
ing techniques such as echocardiography 
may fail to show mild abnormalities that 
precede a classic HCM phenotype. In 
one study, as many as 10% of mutation 
carriers with normal echocardiogram 
had some degree of LV hypertrophy at 
MR imaging (127). Furthermore, MR has 
shown great promise in the identifica-
tion of genotype-positive individuals with 
phenotypic manifestations other than LV 
hypertrophy —a transition between pure 
mutation carrier status and overt HCM 
(Table 1) (29). For example, genotype-
positive individuals may exhibit increased 
mitral leaflet dimensions (38), a trait sim-
ilar to that seen in overt HCM. Further-
more, deep myocardial crypts are found 
in up to 81% of genotype-positive indi-
viduals without LV hypertrophy (Fig 14; 
Movie 6 [online]), compared with 6% in 
healthy volunteers (42,43). Notably, the 
identification of myocardial crypts is en-
hanced by use of additional nonconven-
tional imaging planes, such as an addi-
tional stack of horizontal long-axis cine 
images through the inferior part of the LV 
(128). Another, recently described mor-
phologic marker for HCM is the presence 
of an accessory apical-basal muscle bun-
dle in the LV cavity, present in 63% of 
probands, in 60% of genotype-positive/
phenotype-negative family members, but 
in only 10% of controls (129).
Recently, Ho et al (87), using T1-
mapping, found increased myocardial 
extracellular volume in mutation car-
riers without LV hypertrophy, support-
ing the view that fibrotic remodeling 
is an early feature in the pathogenesis 
of the disease. T1 measurements cor-
related well with markers of collagen 
synthesis, suggesting that this technique 
may help monitor disease progression as 
well as to evaluate novel disease modify-
ing therapy, targeting interstitial fibrosis.
Conclusion
After more than 50 years of extensive 
research, our understanding of the 
clinical spectrum of HCM has grown to 
an extent that would have been hardly 
predictable at the beginning of this 
journey. As the formidable complexity 
of HCM pathophysiology is being un-
raveled, new tools become necessary 
to address the central issues ultimately 
relevant for prevention and treatment. 
Few options like MR offer the opportu-
nity of investigating the diverse morpho-
logic, functional, and metabolic aspects 
of HCM hearts in vivo, opening novel 
avenues for the next half-century of in-
vestigation into this fascinating disease.
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